Osteoarthritis
Tanezumab reduces osteoarthritic knee pain but increases adverse events
J Pain. 2012 Aug;13(8):790-8. doi: 10.1016/j.jpain.2012.05.006. Epub 2012 Jul 10.690 patients with osteoarthritis of the knee were randomized to receive 2.5 mg of tanezumab, 5 mg of tanezumab, 10 mg of tanezumab, or a placebo. The results of the study indicate that the patients treated with tanezumab experienced a significant improvement in knee pain and function, but also an incidence of adverse events of 55 to 60%. It should be noted that the tanezumab osteoarthritis clinical trial is on hold due to potential adverse events leading to joint replacement.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
